RayzeBio, Inc., a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today announced that Ken Song, M.D., President and CEO of the Company, will be presenting at the 40th Annual J.P. Morgan Healthcare Conference being held virtually on Tuesday, January 11, 2022.
J.P. Morgan Healthcare Conference
Date: Tuesday, January 11, 2022
Time: 11:00 a.m. - 11:25 a.m. EST
Please click on the below link to find additional details about the J.P. Morgan Healthcare Conference
https://www.jpmorgan.com/solutions/cib/insights/health-care-conference
About RayzeBio
RayzeBio, Inc., located in San Diego, CA, is a biotechnology company focused on improving outcomes for people with cancer by harnessing the power of targeted radioisotopes. With a focus on clinically validated solid tumor targets, RayzeBio is developing novel drug conjugates to deliver potent therapeutic radioisotopes such as Actinium-225, an alpha-emitter. The company is backed by a syndicate of sophisticated healthcare investors and was established in 2020. For additional information, please visit www.rayzebio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005175/en/
Contacts
Arvind Kush
info@rayzebio.com
